News >

Expert Highlights Nuances in HER2-Positive Breast Cancer Care

Caroline Seymour
Published: Thursday, Jun 21, 2018

Zahi Mitri, MD

Zahi Mitri, MD

The adjuvant setting in HER2-positive breast cancer has become more varied over the past year, most recently with findings of the phase III PERSEPHEONE trial, which showed that 6 months of trastuzumab (Herceptin) was noninferior to the standard 12 months of the HER2-directed agent, supporting a shortened duration of treatment.1

State of the Science Summit™ on Breast Cancer, Zahi Mitri, MD, assistant professor of medicine, Oregon Health and Science University, and chair of the meeting, discussed these adjuvant advances and other emerging trends in the treatment of patients with HER2-positive breast cancer.

OncLive: What are some of the key takeaways from your discussion of the evolving treatment landscape in HER2-positive breast cancer?

Mitri: The presentation at the 2017 San Antonio Breast Cancer Symposium on the NSABP B-47 trial showed and confirmed that patients who have HER2 amplification are those who benefit from HER2-directed therapy.

In metastatic disease, I touched on the roles of pertuzumab, as well as ado-trastuzumab emtansine (T-DM1; Kadcyla), in the management of metastatic HER2-positive breast cancer and went over some of the new agents in development. These are exciting novel anti-HER2 therapies that are coming through the pipeline. 

What are your thoughts on the available adjuvant therapies?

The findings from the APHINITY study were statistically significant. However, at this point, we haven't changed much of our treatment. We still use pertuzumab for the indication it was approved—in the neoadjuvant setting for tumors greater than 2 cm or that are node positive.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication